217 related articles for article (PubMed ID: 32865783)
1. Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy.
Aslesh T; Yokota T
Methods Mol Biol; 2020; 2176():69-85. PubMed ID: 32865783
[TBL] [Abstract][Full Text] [Related]
2. Development of Antisense Oligonucleotide Gapmers for the Treatment of Huntington's Disease.
Aslesh T; Yokota T
Methods Mol Biol; 2020; 2176():57-67. PubMed ID: 32865782
[TBL] [Abstract][Full Text] [Related]
3. Development and Clinical Applications of Antisense Oligonucleotide Gapmers.
Chan L; Yokota T
Methods Mol Biol; 2020; 2176():21-47. PubMed ID: 32865780
[TBL] [Abstract][Full Text] [Related]
4. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
5. Invention and Early History of Gapmers.
Lim KRQ; Yokota T
Methods Mol Biol; 2020; 2176():3-19. PubMed ID: 32865779
[TBL] [Abstract][Full Text] [Related]
6. Knocking Down Long Noncoding RNAs Using Antisense Oligonucleotide Gapmers.
Maruyama R; Yokota T
Methods Mol Biol; 2020; 2176():49-56. PubMed ID: 32865781
[TBL] [Abstract][Full Text] [Related]
7. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
[TBL] [Abstract][Full Text] [Related]
8. Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro.
Chen S; Le BT; Chakravarthy M; Kosbar TR; Veedu RN
Sci Rep; 2019 Apr; 9(1):6078. PubMed ID: 30988454
[TBL] [Abstract][Full Text] [Related]
9. Volanesorsen: First Global Approval.
Paik J; Duggan S
Drugs; 2019 Aug; 79(12):1349-1354. PubMed ID: 31301033
[TBL] [Abstract][Full Text] [Related]
10. Nusinersen in the Treatment of Spinal Muscular Atrophy.
Goodkey K; Aslesh T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
12. Eteplirsen: First Global Approval.
Syed YY
Drugs; 2016 Nov; 76(17):1699-1704. PubMed ID: 27807823
[TBL] [Abstract][Full Text] [Related]
13. An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases.
Rodrigues M; Yokota T
Methods Mol Biol; 2018; 1828():31-55. PubMed ID: 30171533
[TBL] [Abstract][Full Text] [Related]
14. FDA-Approved Oligonucleotide Therapies in 2017.
Stein CA; Castanotto D
Mol Ther; 2017 May; 25(5):1069-1075. PubMed ID: 28366767
[TBL] [Abstract][Full Text] [Related]
15. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
Rocha NA; East C; Zhang J; McCullough PA
Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
[TBL] [Abstract][Full Text] [Related]
16. Antisense technology: an emerging platform for cardiovascular disease therapeutics.
Lee RG; Crosby J; Baker BF; Graham MJ; Crooke RM
J Cardiovasc Transl Res; 2013 Dec; 6(6):969-80. PubMed ID: 23856914
[TBL] [Abstract][Full Text] [Related]
17. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides.
Aartsma-Rus A
Nucleic Acid Ther; 2017 Apr; 27(2):67-69. PubMed ID: 28346110
[No Abstract] [Full Text] [Related]
18. Genetic therapies for inherited neuromuscular disorders.
Scoto M; Finkel R; Mercuri E; Muntoni F
Lancet Child Adolesc Health; 2018 Aug; 2(8):600-609. PubMed ID: 30119719
[TBL] [Abstract][Full Text] [Related]
19. Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia.
Toth PP
J Clin Lipidol; 2013; 7(3 Suppl):S6-10. PubMed ID: 23642326
[TBL] [Abstract][Full Text] [Related]
20. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.
Holm A; Hansen SN; Klitgaard H; Kauppinen S
RNA Biol; 2022; 19(1):594-608. PubMed ID: 35482908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
